Royalty Pharma Stock (NASDAQ:RPRX)

Royalty Pharma plc, headquartered in New York City and founded in 1996, operates within the United States as a key player in the biopharmaceutical industry. The company primarily focuses on the acquisition of royalties from biopharmaceutical products and actively invests in funding new developments and innovations in the sector. Its activities involve diligently identifying, evaluating, and securing royalty agreements for a wide array of biopharmaceutical therapies. Beyond acquisitions, Royalty Pharma plc fosters collaborations with various innovators. These partners include academic institutions, research hospitals, non-profit organizations, small and mid-sized biotechnology firms, and larger pharmaceutical companies. The firm's substantial portfolio includes royalty interests in approximately 35 commercially available treatments and an additional 10 product candidates currently in different stages of development. These assets span a diverse range of critical therapeutic areas, such as rare diseases, cancer, neurological conditions, infectious diseases, hematology, and diabetes.